Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Lubiprostone for Chronic Idiopathic Constipation Treatment
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 211
- Registration Number
- NCT02729909
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
Phase 1
Completed
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02728895
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States
TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TAK-020 SDTDrug: TAK-020 Captisol Oral SolutionDrug: TAK-020 CCTDrug: TAK-020 IRTDrug: TAK-020 Solid Formulation
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 25
- Registration Number
- NCT02723201
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: TAK-788
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 334
- Registration Number
- NCT02716116
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Lumi Research, Houston, Texas, United States
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants
Phase 2
Withdrawn
- Conditions
- Influenza Prevention
- Interventions
- Drug: TAK-850
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Takeda
- Registration Number
- NCT02713061
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants
Phase 1
Completed
- Conditions
- Dose Finding Study
- Interventions
- Drug: TAK-828Drug: Placebo
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT02706834
Lubiprostone for Treatment of Chronic Idiopathic Constipation
Phase 3
Completed
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Drug: PlaceboDrug: Lubiprostone
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 156
- Registration Number
- NCT02695719
Phase 1, TAK-648, Single-Rising Dose Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-648Drug: TAK-648 Placebo
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 39
- Registration Number
- NCT02684396
RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional Study
Completed
- Conditions
- Laparoscopy
- Interventions
- Other: Tachosil
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 131
- Registration Number
- NCT02685007
- Locations
- 🇦🇹
LKH Universitatsklinikum Graz Universitatklinik fur Chirurgie; Abteilung fur Allgemeinchirurgie, Graz, Austria
🇦🇹Landeskrankenhaus Hall; Allgemeine Chirurgie, Hall in Tirol, Austria
🇦🇹Landeskrankenhaus Salzburg/SALK Universitatsklinikum der PMU; Univ.-Klinik fur Urologie und Andrologie, Salzburg, Austria
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3599
- Registration Number
- NCT02678676
© Copyright 2025. All Rights Reserved by MedPath